SCHEMBL5583489

SCHEMBL5583489

O=C(O)C1=NNC=CC=C1

nearest known ligand 0.00

⚠ Novel chemotype — no close known analogue (best Tanimoto < 0.3). Unexplored chemical space relative to ChEMBL.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Piperazine SCHEMBL7414302 0.86
SCHEMBL3969262 0.81
Hydrochloric Acid SCHEMBL3963502 0.79
Pyrrole SCHEMBL18797670 0.72
SCHEMBL460674 0.69
SCHEMBL3542282 0.67
SCHEMBL16238310 0.67
SCHEMBL8428656 0.64 KMT2A (0.36)
SCHEMBL8902925 0.64 HTT (0.32)
SCHEMBL5912864 0.62

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 25 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-5880122-A TREATING DISEASES CHARACTERIZED BY EXCESS RENAL REABSORPTION OF WATER AMERICAN HOME PRODUCTS CORPORATION (US) 1999-03-09 US claimed
US-4118386-A Synthesis of imidazo[1,5-a]diazepine-3-carboxylates HOFFMANN-LA ROCHE INC. (US) 1978-10-03 US claimed
CN-118146289-A Positive and negative regulation NAMPT and NAD+Optically controlled PROTAC compounds and uses thereof 中国人民解放军海军军医大学 2024-06-07 CN disclosed
CN-112601749-B Benzodiazepine derivatives, compositions and methods for treating cognitive impairment 艾吉因生物股份有限公司 2024-03-26 CN disclosed
EP-3654968-B1 METALLO-BETA-LACTAMASE INHIBITORS AND METHODS OF USE THEREOF MERCK SHARP & DOHME LLC (US) 2023-08-16 EP disclosed
EP-3313828-B1 METALLO-BETA-LACTAMASE INHIBITORS MERCK SHARP & DOHME LLC (US) 2023-07-12 EP disclosed
CN-115433211-A Pyrazidopyridone methionine adenosyltransferase 2A inhibitors 南京正大天晴制药有限公司 2022-12-06 CN disclosed
CN-115151561-A Targeted autophagy conjugates and methods 前沿药品公司 2022-10-04 CN disclosed
CN-109790170-B GABA (A) receptor modulators and methods of controlling airway hyperresponsiveness and inflammation in asthma UWM研究基金会有限公司 2022-08-02 CN disclosed
US-20210289794-A1 COMPOSITIONS AND RELATED METHODS FOR AGRICULTURE FLAGSHIP PIONEERING INNOVATIONS V, INC. 2021-09-23 US disclosed
WO-2016154031-A1 GABAERGIC LIGANDS AND THEIR USES UWM RESEARCH FOUNDATION, INC. (US) 2016-09-29 WO disclosed
CN-1197849-C 2,3,4,5-tetrahydro-1H-[1,4] benzodiazepine-3-hydroxamic acid as matrix metalloproteinase inhibitors AMERICAN CYANAMID CO (US) 2005-04-20 CN disclosed
WO-2004017908-A2 CALCIUM RECEPTOR MODULATING COMPOUND AND USE THEREOF TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2004-03-04 WO disclosed
CN-1337952-A 2,3,4, 5-tetrahydro-1H- [1,4] benzodiazepine-3-hydroxamic acids as matrix metalloproteinase inhibitors AMERICAN CYANAMID CO (US) 2002-02-27 CN disclosed
EP-1021444-A1 3-CARBOXAMIDE DERIVATIVES OF 5H-PYRROLO[2,1-c][1,4]-BENZODIAZEPINES AMERICAN HOME PRODUCTS CORPORATION (US) 2000-07-26 EP disclosed
US-5962450-A SEDATIVE HOFFMANN-LA ROCHE INC. (US) 1999-10-05 US disclosed
US-5885986-A CLEAVING, N-ALKYLATING AND REDUCING THE INTERMEDIATE FORMED BY REACTING AN OXAZOLYL AND THIAZOLYLIMIDAZOBENZO AND THIENODIAZEPINE DERIVATIVES WITH AMINE COMPOUNDS; USED AS ANXIOLYTIC AND ANTICONVULSANT OR SEDATIVE-HYPNOTIC AGENTS HOFFMANN-LA ROCHE INC. (US) 1999-03-23 US disclosed
US-5880122-A TREATING DISEASES CHARACTERIZED BY EXCESS RENAL REABSORPTION OF WATER AMERICAN HOME PRODUCTS CORPORATION (US) 1999-03-09 US disclosed
WO-1998020011-A1 3-CARBOXAMIDE DERIVATIVES OF 5H-PYRROLO[2,1-c][1,4]-BENZODIAZEPINES AMERICAN HOME PRODUCTS CORPORATION (US) 1998-05-14 WO disclosed
US-4118386-A Synthesis of imidazo[1,5-a]diazepine-3-carboxylates HOFFMANN-LA ROCHE INC. (US) 1978-10-03 US disclosed